Gossamer Bio Inc (GOSS)

$0.7

+0.03

(+4.66%)▲

Market is closed - opens 8 PM, 25 Nov 2024

Performance

  • $0.67
    $0.71
    $0.70
    downward going graph

    3.71%

    Downside

    Day's Volatility :5.16%

    Upside

    1.5%

    downward going graph
  • $0.50
    $1.60
    $0.70
    downward going graph

    28.67%

    Downside

    52 Weeks Volatility :68.79%

    Upside

    56.25%

    downward going graph

Returns

PeriodGossamer Bio IncSector (Health Care)Index (Russel 2000)
3 Months
-25.42%
-6.9%
0.0%
6 Months
4.09%
-1.7%
0.0%
1 Year
-8.96%
10.4%
0.0%
3 Years
-94.09%
8.8%
-24.1%

Highlights

Market Capitalization
162.0M
Book Value
$0.24
Earnings Per Share (EPS)
-0.24
Wall Street Target Price
6.719
Profit Margin
-68.03%
Operating Margin TTM
-357.8%
Return On Assets TTM
-11.24%
Return On Equity TTM
-90.26%
Revenue TTM
105.3M
Revenue Per Share TTM
0.47
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-61.8M
Diluted Eps TTM
-0.24
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.28
EPS Estimate Next Year
-0.7
EPS Estimate Current Quarter
-0.15
EPS Estimate Next Quarter
-0.15

Analyst Recommendation

Buy
    68%Buy
    31%Hold
    0
    0%Sell
Based on 16 Wall street analysts offering stock ratings for Gossamer Bio Inc(by analysts ranked 0 to 5 stars)
Based on 16 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
11
11
11
Hold
5
5
5
Sell
00
00
1

Analyst Forecast

What analysts predicted

Upside of 859.83%

Current $0.70
Target $6.72

Technicals Summary

Sell

Neutral

Buy

Gossamer Bio Inc is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Gossamer Bio Inc
Gossamer Bio Inc
-25.28%
4.09%
-8.96%
-94.09%
-97.34%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-22.64%
-24.32%
-6.91%
15.67%
106.43%
Biontech Se
Biontech Se
-2.39%
5.8%
10.48%
-66.36%
407.41%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-16.76%
63.55%
51.52%
31.97%
130.85%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-5.17%
0.63%
27.5%
148.14%
106.59%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Gossamer Bio Inc
Gossamer Bio Inc
NA
NA
NA
-0.28
-0.9
-0.11
NA
0.24
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
18.38
18.38
1.11
44.91
0.17
0.07
NA
272.04
Biontech Se
Biontech Se
160.8
NA
0.04
-3.04
-0.02
-0.01
NA
79.73
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-0.17
-15.01
-0.03
NA
0.25
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.18
0.54
-0.03
0.12
NA
60.65
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Gossamer Bio Inc
Gossamer Bio Inc
Buy
$162.0M
-97.34%
NA
-68.03%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$81.7B
106.43%
18.38
33.61%
Biontech Se
Biontech Se
Buy
$24.5B
407.41%
160.8
-15.36%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.1B
130.85%
NA
-15.86%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$116.2B
106.59%
32.84
-4.51%

Insights on Gossamer Bio Inc

  • Vs ALNY

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 51.5% return, outperforming this stock by 60.5%

  • Vs VRTX

    In the last 3 years, Vertex Pharmaceuticals Incorporated has given 32.0% return, outperforming this stock by 126.1%

Institutional Holdings

  • NEA Management Company, LLC

    7.98%

  • Artal Group S A

    5.87%

  • Vanguard Group Inc

    5.19%

  • Octagon Capital Advisors LP

    4.05%

  • ARCH VENTURE CORP

    3.56%

  • FMR Inc

    3.50%

Company Information

gossamer bio is a san diego-based company focused on the discovery and development of novel and differentiated therapeutic products, to address high unmet needs amongst various targeted patient populations. founded by the former receptos executive team, gossamer bio’s strategy will be to leverage an asset-rich in-licensing environment, with a focus on areas of high unmet need, utilizing a team with a strong track record of execution in immunology, inflammation, fibrosis and oncology.

Organization
Gossamer Bio Inc
Employees
135
CEO
Mr. Faheem Hasnain
Industry
Pharmaceuticals: Major

FAQs